Study of the effectiveness and safety of the drug Mexol Fort 250 as part of consecutive therapy in patients with a hemisphere ischemic stroke in acute and early recovery periods

Authors:
M.A. Loskutnikov, M.A. Domashenko, T.M. Vakin, I.A. Trushina, V.I. Konstantinov, O.S. Proskuryakova, E.P. Schukina

ANO "Central Clinical Medicine-Sanitary Part", Magnitogorsk, Russia

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2020, T. 120, No. 10

Summary:
Purpose of the study. Evaluate the effectiveness and safety of consistent therapy with Mexidol drugs (a solution for iv and iv in the administration) and Mexidol Forte 250 (tablets covered with a shell) in patients with a hemispherral ischemic stroke in an acute and early recovery periods. Material and methods. At the time of the end of the therapy, the dynamics on the modified Rankin scale (MRS), the test results on the stroke of the National Institute of Health (NIHSS), the Bartel (BI), the Montreal Cognitive Functions Assessment (MOCA), the BEK questionnaire (BDI), the questionnaire questionnaire (BDI). Evaluation of the quality of life (EQ-5D). Results and conclusion. Consistent long -term therapy with Mexidol with a dosage of 500 mg/day for 14 days (saturation phase) and Mexol Forte 250 by 250 mg 3 times a day for 60 days (phase of maximization of the therapeutic effect) provides additional opportunities for more complete restoration in acute and acute and acute and acute The early recovery periods of the hemisphere stroke (improves the quality of life, improves the restoration of motor and cognitive functions). Keywords: Holding ischemic stroke, Mexidol Fort 250, acute and early recovery periods, quality of life.